ClinicalTrials.gg
CompletedNCT03044054HIFU-003Updated May 1, 2026

Treatment of Breast Fibroadenoma Targeted Tissue With HIFU

An interventional study of ECHOPULSE in Breast Fibroadenoma, sponsored by Theraclion. Completed at 4 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Theraclion · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
113
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This study evaluates the efficacy and the safety of the HIFU for the treatment of breast fibroadenoma.

Read the detailed description

Echopulse is specially designed, manufactured and CE marked for treating breast fibroadenoma. HIFU is a completely alternative to surgery which utilizes high-energy ultrasound to deliver a large amount of sound energy to a focal point to rapidly induce tissue heating to 85-90°C.This initiates tissue coagulation followed by tissue necrosis ablating the targeted area.

02

Conditions studied

  • Breast Fibroadenoma

Browse trials for

Keywords

  • HIFU
03

In context

Fibroadenoma

27 studies on the registry are indexed under Fibroadenoma; 6 are open to participants now.

This study's enrollment of 113 is above the median of 50 across 20 interventional studies indexed under Fibroadenoma.

Browse Fibroadenoma studies →

Lead sponsor

Theraclion is the lead sponsor of 18 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients 18 years or older diagnosed with breast fibroadenoma and presenting at least one fibroadenoma.
  2. Diagnosis of fibroadenoma must be based on:

    1. Clinical examination
    2. Ultrasound image alone for patients under 35 years old. For women older than 35 years, a mammogram will be performed in addition to ultrasound. The BI-RADS score of this mammogram must be 2 or 3. BI-RADS score of 4 is eligible if indicates fibroadenoma with concordance.
    3. Histologic confirmation by core needle biopsy.
  3. Patient is a candidate for the surgery.
  4. The fibroadenoma treatment volume must be at least 5 mm and no more than 26 mm from the skin. This criterion should be evaluated immediately prior treatment, once the breast is immobilized and potentially compressed.
  5. The rib cage should not be in the prefocal ultrasound path or behind the target fibroadenoma (minimum distance from the posterior wall of the fibroadenoma must be at least 10 mm). This criterion shall be evaluated immediately prior to treatment, once breast is immobilized and potentially compressed.
  6. The fibroadenoma is 1 cm or greater at its largest dimension and no less than 7.5 mm in the anterior-posterior dimension (measured by ultrasound). Focal point for HIFU treatment must also be at least 3 mm from any border of the fibroadenoma.
  7. Patient's fibroadenoma size is greater or equal to 0.2 cc and less than 10 cc in volume (measured by ultrasound on the day of the procedure).
  8. Fibroadenoma is palpable.
  9. Pain ≥ 30mm/100mm measured on VAS as a maximum level during the last 30 days
  10. Anxiety ≥ 30mm/100mm measured on VAS as a maximum level during the last 30 days
  11. Patient has signed a written .

Exclusion criteria

Exclusion Criteria:

  1. Patient is pregnant or nursing.
  2. Presence of calcified fibroadenoma. Calcification will be determined with mammography. In women > 35 years old, the diagnostic mammogram should be evaluated for calcification. In women ≤ 35 years old, a single view mammogram of the affected breast is sufficient for evaluation of calcification. Women ≤ 35 years old will be excluded based on the findings of calcification on a single view mammogram.
  3. Patient with history of breast cancer or history of laser or radiation therapy to the target breast.
  4. Patient with breast implants in the target breast.
  5. Patient with a breast cyst within the fibroadenoma to be treated.
  6. Patient's fibroadenoma not clearly visible on the ultrasound images (in B mode) at the inclusion visit.
  7. Patient participating in another clinical trial involving an drug, device or biologic.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Enrollment
113 participants (actual)

Study arms

  • Experimental
    ECHOPULSE

    ECHOPULSE HIFU

    Device: ECHOPULSE

Interventions

  • DeviceECHOPULSE

    HIFU Under ultrasound guidance

06

What researchers measure

Primary outcomes

  1. Pain level assessment

    visual analog scale

    Time frame: 12 Months

  2. Anxiety level assessment

    visual analog scale

    Time frame: 12 Months

  3. Volume assessment

    Ultrasound measurement

    Time frame: 12 Months

Secondary outcomes

  1. The short (6-item) version of the State-Trait Anxiety Inventory (STAI)

    Time frame: inclusion visit (V0), Day 2/3, Day 7, 6 months, 12 months

  2. Palpability of the breast fibroadenoma

    Physician clinical examination

    Time frame: inclusion visit (V0), Day 2/3, Day 7, 6 months, 12 months

  3. Freedom from additional procedures for fibroadenoma of the breast

    Physician assessment concerning the need of additional procedures

    Time frame: Day 2/3, Day 7, 6 months, 12 months

  4. Patient satisfaction

    Self assessment satisfaction questionnaire

    Time frame: Month 6 and Months 12

  5. Safety endpoints include adverse events (AEs) and serious adverse events (SAEs) occurring at any time during the trial.

    Assessment and capture of adverse events

    Time frame: Day 0, Day 2/3, Day 7, 6 months, 12 months

07

Study locations

4 sites
  • Bellevue Hospital Center
    New York, New York 10016, United States
  • New York Columbia University Medical Center
    New York, New York 10032, United States
  • Montefiore-Einstein Center for Cancer Care
    New York, New York, United States
  • University of Virginia Health system
    Charlottesville, Virginia 22903, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Mar 2026, 110 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2017
First posted
Feb 6, 2017
StartActual
Jan 2017
Primary completionActual
Mar 2026
CompletionActual
Apr 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03044054
Lead sponsor
Theraclion
Responsible party
Sponsor
First posted
Feb 6, 2017
Start date
Jan 2017
Primary completion
Mar 2026
Completion
Apr 2026
Last update
May 1, 2026

Study contacts

Michel NUTA, MD
study director · Theraclion

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion